HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

The Gillette Fusion shaving system generated retail sales of more than $220 mil. within the first seven months of its January launch, Procter & Gamble President and CEO A.G. Lafley states during the firm's annual shareholder meeting Oct. 10. P&G estimated the product would achieve $1 bil. in sales by its third year on shelves (1"The Rose Sheet" Sept. 19, 2005, p. 7). Additionally, the exec updated analysts on the firm's progress in integrating Gillette, which the personal care company acquired for $57 bil. in early 2005 (2"The Rose Sheet" Jan. 31, 2005, p. 3). Nearly 80% of Gillette and P&G commercial operations will be integrated by the end of October, 2006, Lafley notes. "We've managed all these integration details while delivering business and financial commitments on the established businesses," he adds...

You may also be interested in...

Gillette Upgrades To Five Blades With Fusion Razor Collection

Gillette anticipates the Fusion five-blade razor collection will achieve $1 bil. in sales within its third year on shelves, according to Blades & Razors President Peter Hoffman. The firm unveiled the line of manual and powered shavers, slated to launch in the first quarter of 2006, at a Sept. 14 press conference in New York City

P&G $57 Bil. Gillette Acquisition Creates 21 Billion-Dollar Brand Portfolio

Procter & Gamble will acquire Gillette in a stock transaction valued at $57 bil., creating a consumer products powerhouse with combined sales of over $60 bil. and a portfolio that includes 21 billion-dollar brands, the two firms announced at a news conference in New York City Jan. 28

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts